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We investigated the radiolabeling efficiency, in vitro stability, and biodistribution of radioactive iodine (131I)-labeled 4-benzoyl-1- 
(4-carboxyphenyl)-5-phenyl-1H-pyrazole-3-carboxylic acid (P3CA). A quality-control study of the labeled substance (131I-P3CA) 
was conducted using electrophoresis and radio thin-layer chromatography (RTLC). Biodistribution studies were undertaken in 9 
female albino Wistar rats. Rats were killed at various times (15, 60 and 180 min), their organs removed, and percentage of injected 
dose per gram (ID%/g) values calculated. The labeling yield of P3CA was 97.08%±0.80%. The maximum uptake of 131I-P3CA 
was seen in the lungs, stomach and spleen at 15 min. The uptake of labeled compound decreased over time in the lungs, whereas 
that in the stomach decreased. These data suggest that 131I-P3CA had high binding efficiency, high uptake in the lung, and suffi-
cient stability to be used in diagnostic studies.  
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Radiopharmaceuticals have been used in nuclear medicine 
as tracers in diagnosing and treating several diseases. Radi-
onuclides and radiopharmaceuticals are used widely for 
different purposes. Radioactive iodine (131I) is used routinely 
in nuclear medicine. Chemotherapy with 131I (first intro-
duced in 1946 for the treatment of thyroid cancer) is the 
most efficacious method for treating hyperthyroidism and 
thyroid cancer.  
Pyrazole derivatives are a class of heterocyclic compound 
containing 1,2 diazole systems [1]. They are important sub-
stances and have gained widespread attention due to their bio-
logical activities. Several studies have revealed that pyrazoles 
have important properties: antimicrobial [2,3] analgesic [4,5], 
antiviral [6,7], antitumor [8,9], anti-inflammatory [10,11], 
cytotoxic [12], antihistaminic [13], pesticidal [14], antifungal 
[15,16], anticonvulsant [17] and antidepressant [18].  
Several studies have investigated the synthesis and char-
acterization of different pyrazole-containing ring systems 
endowed with potential chemotherapeutic activities [19–21]. 
Pyrazoles are known to exert anticancer effects by inhibit-
ing enzymes that have important roles in cell division [22]. 
The Biological Committee of the National Cancer Institute 
has selected three pyrazole compounds to optimize the ex-
posure time to these agents and to define their possible 
mechanisms of action using in vivo studies [23].  
The antibacterial activity of 4-benzoyl-1-(4-carboxyphenyl)- 
5-phenyl-1H-pyrazole-3-carboxylic acid (P3CA) affects Gram- 
positive and Gram-negative bacteria [3]. The biodistribution 
of P3CA has not been investigated. The purpose of the pre-
sent study was the labeling of P3CA with 131I and to determine 
the radiopharmaceutical potential of the labeled compound.  
1  Materials and methods 
All reagents were: available commercially; of analytical grade; 
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used without further purification. 4-benzoyl-1-(4-carboxy-     
phenyl)-5-phenyl-1H-pyrazole-3-carboxylic acid was pro-
vided by the Organic Chemistry Division, Yuzuncu Yil 
University (Van, Turkey). 131I was obtained from the De-
partment of Nuclear Medicine, Ege University (Izmir, Turkey).  
1.1  Labeling procedure 
(1) Synthesis of inactive I-P3CA.  Inactive I-P3CA was 
synthesized according to the method of Akhlaghinia and 
Rahmanib, with slight modifications [24]. P3CA (20.0 mg, 
0.05 mmol), iodogen (21.2 mg, 0.05 mmol), SiO2 (25.0 mg, 
0.42 mmol), and iodine (12.4 mg, 0.05 mmol) were dis-
solved in 5.0 mL methane dichloride. Next, we added 3.0 mL 
methanol and 25.0 mL distilled water to the mixture and 
stirred it for 30 min at room temperature. Sodium thiosul-
fide (10%) was added over the solution until the dark-orange 
color disappeared. The progress of the reaction was moni-
tored by thin-layer chromatography (TLC). When the reac-
tion was complete, the solvent was removed by vacuum, 
and the residue washed with methane dichloride (5.0 mL). 
The precipitate was dissolved in methanol to separate the 
impurities, and the solvent removed by vacuum. The residue 
was dried over anhydrous MgSO4 to provide inactive 
I-P3CA.  
(2) Synthesis of 131I-P3CA.  131I-P3CA was synthesized 
according to the method of Mertens [25]. A solution of 
I-P3CA (5.0 mg in 20.0 L DMSO) was mixed with a solu-
tion of ascorbic acid (2.0 mg in 200.0 L distilled water). 
Next, 10.0 L CuSO4 (1.0 mg CuSO4/40.0 mL distilled water) 
and 400.0 L (10 mCi/mL) Na131I were added to the solu-
tion and mixed for 2 h at 100°C. The solution was allowed 
to stand at room temperature for 12 h to obtain 131I-P3CA. 
(3) Oxidation of 131I.  An iodogen (1.0 mg)-coated ep-
pendorf tube was charged with 500 μCi of Na131I. The reac-
tion mixture was allowed to stand at room temperature for 
25 min without stirring. After 25 min, quality controls were 
checked. During the labeling of 131I-P3CA, there are three 
types of radioactive iodine. The first one is oxidized and 
connected to P3CA. The second one is oxidized but does 
not react with P3CA. The third one is neither oxidized nor 
does it react with P3CA. The oxidation of 131I was conduct-
ed to find unreacted oxidized 131I. 
1.2  Quality controls 
The following quality-control studies were done with radio 
thin-layer chromatography (RTLC) and paper electrophore-
sis to confirm the labeling efficiency of 131I-P3CA. 
(1) RTLC procedure.  Each RTLC cellulose-coated plate 
was covered with a cello-band after its development and cut 
into widths of 0.5 cm. Various solvent mixtures were used 
as developers [(solvent A: acetic acid, water, n-butanol; 1/2/4, 
v/v/v), (solvent B: water, DMSO, ethyl alcohol; 1/2/5/, 
v/v/v), (solvent C: distilled water)]. The developed sheet 
was dried and cut into widths of 0.5 cm. Radioactivity on 
the plates was measured using a Cd(Te) detector equipped 
with a RAD 501 single-channel analyzer. RTLC figures 
were obtained by plotting counts versus distance. Rf values 
and labeling yields were derived from these chromatograms. 
(2) Paper electrophoresis.  Electrophoresis was achieved 
with a Gelman Electrophoresis Chamber, model 51170. The 
cathode and anode poles and application points were indi-
cated on cellulose strips moistened by Physiologic Serum 
Solution (0.9% NaCl). After the samples were set onto the 
strips, they were placed in the electrophoresis chamber. 
During 2 h, a voltage of 300 V was applied. Developed 
strips were dried and cut into 1-cm pieces. The amount of 
radioactivity in each sample was quantified using a radia-
tion monitor, RAD-501, single-channel analyzer. 
1.3  Lipophilicity  
A 100.0-L aliquot of the labeled sample was mixed with  
3 mL of 1-octanol and 3 mL of water in a test tube. The 
tube was vortex-mixed (3×1 min), incubated for 1 h at room 
temperature, and centrifuged at 3000 r/min for 5 min. Then, 
0.5-mL aliquots were taken from each phase for counting. 
The partition coefficient=logP (counts in n-octanol lay-
er/counts in aqueous layer). 
1.4  Serum and physiological serum stability of 131I-P3CA 
131I-P3CA (300.0 L) was incubated with 600.0 L of fresh 
human and physiological serum at 37°C for 4 h. During 
incubation, labeled substances were examined at 15 min and 
1, 3 and 24 h by RTLC.  
1.5  Biodistribution studies in rats 
Animal experiments were conducted using protocols ap-
proved by the Animal Care and Use Committee of Afyon 
Kocatepe University (Afyonkarahisar, Turkey). The exper-
iments involved female Albino Wistar rats (≈100–140 g). 
Three rats were used for each set of experiments. To pre-
vent iodine uptake by the thyroid gland, 10.0 mg of potas-
sium iodide was added to 1.0 L of the drinking water con-
sumed by the rats. The pH of the 131I-labeled compound was 
adjusted to 7.0 with 1.0% NaOH solution. It was sterilized 
by passing through a 0.22-m membrane filter.  
The compound was injected into the tail vein of rats  
(5.0 mg 131I -P3CA per rat). Rats were killed in an ether 
atmosphere after certain times (15, 60, or 180 min) and their 
organs removed. All collected tissues were weighed and the 
radioactivity of 131I -P3CA calculated as the percentage of 
injected dose per gram (ID%/g). 
1.6  Statistical analyses 
Data are the mean±SD for parametric variables. Parametric 
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variables were compared using Pearson’s correlation and 
one-way analysis of variance with post hoc analyses using 
the Duncan test. P<0.05 were considered significant. 
2  Results and discussion 
The labeled compound is shown in Figure 1. High radio-
labeling efficiency and good stability of radiolabeled sub-
stances are essential for successful immunoconjugate imag-
ing or therapy. The labeling yield of 131I-P3CA was 97.08%± 
0.80%. Electrophoresis revealed 131I-P3CA to be neutral 
(Figure 2) because it did not move toward either electrode.  
Lipophilic substances are soluble in fat. The partition co-
efficient [LogP (counts in n-octanol layer/counts in aqueous 
layer)] of 131I-P3CA was 0.43 (n=3) at pH 7.0. The theo-
retical lipophilic value of 131I-P3CA was calculated using 
the ACD/Labs program and was 5.75.  
We believe that copper forms a complex with I-P3CA 
because it contains nitrogen and oxygen atoms. Therefore, 
we added CuSO4 during the labeling of P3CA with 
131I. 
According to the theoretical value, I-P3CA is more soluble 
in the octanol phase (logP=5.75) than the water phase. How-
ever, the complex of 131I-P3CA with copper is more soluble 
in the water phase; the solubility changes with complex 
formation. Hence, the lipophilic value is also decreased.  
The Rf values for the radioactive compounds are given in 
Table 1. The radiolabeled compound (131I-P3CA) did not  
 
Figure 1  Structure of the labeled compound (131I-P3CA). 
move in any solvent media, but the other radioactive sub-
stances moved from their initial starting point.  
In vitro stability results showed that 131I-P3CA de-     
iodinates with time. The labeling percentages were 97.08%± 
0.80%, 97.05%±2.41%, 97.02%±2.24%, 97.01%±3.28%, and 
96.92%±4.11% at 15, 30, 60, and 180 min and 24 h, respec-
tively (Table 2). The stability decreased very slowly over 
time. According to the serum stability data, the radiolabel-
ing yield was 97.08%±0.80%, 95.56%±3.39%, 95.01%± 
3.83%, 91.43%±4.18%, and 86.46%±9.45% at 15, 30, 60, 
and 180 min and 24 h, respectively (Table 2). These results 
suggest that the radiolabeled compound is suitable for im-
aging. Decreases in serum stability and uptake of physio-
logical serum did not show similar trends across the same 
time period. Serum contains different types of substances 
and metals ions that might affect the structure of 131I-P3CA. 
Hence, the deterioration of 131I-P3CA in serum is faster than 
in physiological serum.  
The biodistribution of 131I-P3CA to all studied organs is 
given (Table 3) in %ID/g. A high uptake of 131I-P3CA was 
observed in the lungs (ID%/g=42.98) at 15 min. This uptake 
of the radio-substance decreased over time (ID%/g=9.65 
and 3.26 at 60 and 180 min, respectively). The other im-
portant organ for 131I-P3CA uptake was the stomach. The 
uptake of 131I-P3CA increased over time (ID%/g 3.30, 3.54 
and 6.37 at 15, 60, and 180 min, respectively) in the stom-
ach. The clearance of 131I-P3CA from the blood (2.78, 0.82 
and 0.46 at 15, 60 and 180 min, respectively) changed 
sharply. A significant amount of 131I-P3CA was absorbed in 
the spleen. The initial uptake of 131I-P3CA was high, then 
decreased and then increased again in the heart, liver, thy-
roid, kidneys, spleen, muscle, intestine, ovaries, pancreas, 
head, spinal cord, and uterus.  
There were significant positive correlations between 
some of the organs (Table 4).  
Effective radiolabeling of P3CA with 131I required the 
adoption of the normal heating method. While labeling 
P3CA with 131I, 14 h elapsed. The reaction time was higher 
than that required for radiolabeling an imidazole derivative 
(131IAZGP) using the 131I–I exchange reaction [26].  
Radiopharmaceuticals can, in general, be categorized on 
the basis of their unique mechanism of localization in a  
 
Figure 2  Electrophoretogram of 131I–, oxidized-131I and 131I-P3CA. 
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Table 1  Rf values of radioactive components in RTLC a) 
Solvent 131I Ox-131I 131I-P3CA 
A 0.25 0.00 0.00 (application point) 
B 1.00 1.00 0.00 
C 0.88 1.00 0.00 
a) Ox-131I: oxidation of iodine (131I); solvent A: n-butanol, water, acetic 
acid (4/2/1, v/v/v); solvent B: DMSO, ethyl alcohol, water (2/5/1, v/v/v); 
solvent C: distilled water. 
Table 2  Stability of 131I-P3CA in physiological serum and human serum 
Time (h) 
Yield (%) 
in physiological serum 
Yield (%) 
in human serum 
0 97.08±0.80 97.08±0.80 
1 97.05±2.41 95.56±3.39 
2 97.02±2.24 95.01±3.83 
3 97.01±3.28 91.43±4.18 
4 96.92±4.11 86.46±9.45 
 
Table 3  Percentage of giving dose per gram (ID%/g) 131I-P3CA in normal rat tissues 15, 60 and 180 min post-injection 
Organ 
15 min  60 min  180 min 
Mean SD  Mean SD  Mean SD 
Heart 0.74 0.14 0.28 0.14 0.91 0.82 
Lung 42.98 1.94 9.65 2.13 3.26 1.24 
Liver 3.63 2.28 1.89 0.83 3.82 2.18 
Kidneys 1.01 0.05 0.39 0.17 0.67 0.13 
Small intestine 1.24 0.73 0.44 0.31 1.11 0.35 
Large intestine 0.72 0.46 1.00 0.69 0.41 0.16 
Stomach 3.30 1.81 3.54 2.44 6.37 1.49 
Spleen  2.10 1.13 0.74 0.25 2.08 0.90 
Pancreas 1.14 0.46 0.49 0.26 0.57 0.20 
Blood 2.78 1.45 0.82 0.31 0.46 0.27 
Muscle 0.69 0.50 0.28 0.30 0.43 0.11 
Ovary 1.45 1.13 0.20 0.13 0.59 0.22 
Thyroid 0.56 0.19 0.27 0.09 0.65 0.15 
Brain 0.23 0.19 0.05 0.04 0.12 0.07 
Spinal cord 0.36 0.33 0.21 0.20 0.44 0.22 
Uterus 1.35 1.05 0.30 0.20 0.73 0.17 
Urinary bladder 2.29 1.59 2.24 2.38 4.02 1.67 
Table 4  Positive correlations between the organs of 131I-P3CA 
Organs r P Organs r P 
Lung-blood 0.85 <0.0030 Pancreas-blood  0.87 <0.0017 
Liver-spleen 0.96 <0.0002 Pancreas-ovary  0.88 <0.0013 
Liver-thyroid  0.85 <0.0030 Pancreas-brain 0.85 <0.0034 
Liver-spinal cord 0.94 <0.0005 Pancreas-uterus 0.85 <0.0031 
Small intestine-spleen 0.90 <0.0007 Blood-ovary 0.91 <0.0005 
Small intestine-ovary 0.86 <0.0024 Blood-brain 0.85 <0.0034 
Small intestine-thyroid 0.91 <0.0005 Muscle-ovary 0.86 <0.0023 
Small intestine-brain 0.85 <0.0033 Muscle-brain 0.85 <0.0036 
Small intestine-spinal cord 0.86 <0.0029 Muscle-uterus 0.91 <0.0006 
Small intestine-uterus 0.89 <0.0010 Ovary-brain 0.97 <0.0001 
Spleen-brain 0.87 <0.0001 Ovary-uterus 0.98 <0.0001 
Spleen-spinal cord 0.90 <0.0009 Brain-uterus  0.93 <0.0002 
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specific tissue/organ. Radiolabeled substances should be 
within an appropriate size range for specific organ uptake or 
biodistribution. For example, uptake in lungs is high for 
particles larger than 10 m [27], so 131I-P3CA uptake in the 
lungs was high. One possible explanation for this finding is 
that 131I-P3CA forms a more complicated complex with 
copper, and this complicated complex may be retained in 
lung capillaries. 
Imidazole derivatives are labeled with different radionu-
clides: 99mTc, 64Cu, 131I, and 18F. For an imidazole derivative 
to connect to a radionuclide, a substance that connects to the 
imidazole derivative and the radionuclide is necessary. 
These substances should contain an aromatic group for nu-
cleophilic substitution with the radioactive halogen group or 
nitrogen, oxygen, phosphorus, and sulfur atoms to create 
compounds with radioactive metals. During the labeling of 
I-P3CA with 131I, I-P3CA could have formed a complex 
with copper, and undergone nucleophilic substitution with 
131I.  
64Cu-labeled two monoclonal antibodies (DOTA-cT84.66 
and DOTA-cBR96, DOTA=1,4,7,10-tetraazacyclododecane- 
1,4,7,10-tetraacetic acid) have high uptake in the lungs at 15 
min, but their uptake decreases over time in the lungs [28]. 
Similar results were obtained in the present study. The 
maximum uptake values for the radioiodinated thymidine 
analog (125I-IUdR) [29] in lung metastases in mice and radi-
olabeled IAZGP [30] in the lungs were ≈0.6 (ID%/g), but 
uptake of 131I-P3CA in the lung was more than that stated 
previously.  
Comparing the biodistribution of 131I-P3CA with that of 
64Cu-NOTA-TRC105 and 64Cu-DOTA-TRC105 ≈4 h after 
injection, 131I-P3CA radioactivity in the blood was signifi-
cantly lower than that of 64Cu-DOTA-TRC105 and 64Cu- 
NOTA-TRC105. According to Zing at al., who reported on 
the biodistribution of 64Cu-labeled monoclonal antibody 
with NOTA and DOTA, the clearance of labeled molecules 
in the blood was considerably slower than what we ob-
served with 131I-P3CA. Some of the processes that metabo-
lize and excrete drugs in the liver and kidneys [31] absorbed 
a considerable part of 131I-P3CA soon after injection into the 
liver and kidneys. The maximum uptake of 131I-P3CA oc-
curred at 180 min in the liver and at 15 min in the kidneys.  
The uptake of 131I-P3CA in the brain was not significant. 
This result was expected because the molecular weight of 
the 131I-P3CA complex with copper is >500 Da. If drugs 
have a low molecular mass (<400–500 Da) and high lipid 
solubility, they can pass through the blood-brain barrier 
readily [32].  
3  Conclusion 
The original goal of the present study was to calculate the 
biodistribution of 131I-P3CA in rats. Additionally, we showed 
that the labeling efficiency of 131I-P3CA was high and that 
131I-P3CA accumulation in the lungs was appreciable. We 
feel that 131I-P3CA has sufficient stability to be used in di-
agnostic studies. If P3CA is labeled with 123I or 64Cu instead 
of 131I, it could prove to be a radiopharmaceutical target for 
lung imaging in single-photon emission computed tomog-
raphy. 
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